DCIS is a form of noninvasive breast cancer that occurs in the milk ducts of the breast. Despite a high cure rate of 98%, it can eventually develop into a malignant tumor. This is why seeking treatment early and understanding your treatment options is so important.
Read more on DCIS Treatment – What Are My Options?…
Read More
As we’re all doing our best adapting to current recommendations to stay at home and avoid going anywhere that isn’t absolutely essential, we also know that many things don’t hit the “pause” button just because our daily habits do.
Read more on How Telemedicine Can Help With Breast Cancer Concerns During COVID-19 …
Read More breast cancer and COVID, breast cancer telehealth, breast cancer telemedicine, breast cancer treatment Knoxville
During the current COVID-19 crisis, we want to reassure you that we are taking every precautionary measure to ensure the safety of our breast cancer patients and our staff.
In adherence to the American College of Surgeons’ guidelines, we are committed and equipped to perform emergent or urgent surgical procedures, while non-urgent and elective surgeries will be rescheduled at a further date once restrictions have been lifted.
Read more on What You Need To Know About Surgeries During The COVID-19 Pandemic…
Read More
The U.S. Food and Drug Administration has recently granted its first approval to an immunotherapy regimen for Triple Negative Breast Cancer, which is significant because Triple Negative Breast Cancer tumors are generally high-grade, aggressive, and typically more likely to spread and recur.
Read more on First Immunotherapy Regimen for Triple-Negative Breast Cancer Approved By FDA…
Read More Immunotherapy for breast cancer, Triple Negative breast cancer treatment
For women diagnosed with hormone-receptor-positive DCIS, a new study has determined that low dose Tamoxifen after surgery reduced the risk of the disease coming back. Low dose tamoxifen also reduced the risk of developing a new invasive breast cancer.
Read more on Low Dose Tamoxifen Reduces Risk Of Recurrence For Some Breast Cancers…
Read More ADH, ALH breast cancers, DCIS, LCIS, reduce breast cancer recurrence
According to the American Cancer Society, pancreatic cancer is currently the third leading cause of cancer-related deaths in the U.S., and rates are rising faster than any other cancer in the country. Researchers predict it will become the second deadliest cancer in the U.S. by 2030, second only to lung cancer.
Read more on New Research Links BRCA2 Breast Cancer Gene With Pancreatic Cancer Risk…
Read More BRCA gene, pancreatic cancer treatment, PARP-I
Hello, Margulies office people!
This is just a quick note to thank you all for all the concern, assistance, and care you have given me over the past month. One month ago today I had the biopsy that came back with a Grade 1 cancer result, and today I’m at work with only a couple of scars and a cute little purple binder covering my cancer-free chest. 🙂 I know there is more treatment ahead of me, but I am very grateful to be so quickly and easily to this point. I can only pray that the rest of the process will be as efficient, straightforward, and reassuring as my experience with your office has been.
Read more on A Special Note Of Gratitude From A Relieved Patient…
Read More Breast cancer surgery, breast cancer treatment Knoxville
Some women who undergo In Vitro Fertilization (IVF) worry that the process may increase their risk of developing breast cancer. It’s estimated that over 8 million babies have been born worldwide as a result of IVF and other advanced fertility treatments since the first IVF birth in 1978. In the U.S., 1.5% of all births are the result of using artificial reproductive therapies, which is the highest percentage to date.
Read more on Does Fertility Treatment Affect Your Risk of Breast Cancer?…
Read More DCIS, IVF and breast cancer
I’m excited to share news about a significant advancement in treatment for patients with HER2-positive early breast cancer. A phase III trial shows that a treatment called Kadcyla® (TDM-1) lowered the risk of recurrence of invasive breast cancer or death by 50% compared to Herceptin® in patients with HER2-positive early breast cancer with residual disease after pre-surgical (neoadjuvant = NST) therapy.
Read more on Encouraging News For Treatment Of HER2-positive Early Breast Cancer…
Read More clinical trials for HER2-positive breast cancer, KadcylaYou’ve most likely seen the ads on TV for home-kits like 23andMe that can tell you about your ancestry through saliva testing. 23andMe is now offering the ability to give you FDA approved health reports as well, and people are curious if these reports can determine if they carry the BRCA1 and BRCA2 genes, which increase the risk of breast and ovarian cancer.
Read more on Concerns About Genetic Testing Kits For Detecting Breast Cancer Genes…
Read More Breast Cancer Genes, Detecting Breast Cancer Genes, Genetic testing, Genetic Testing Kits